Homogeneous and heterogeneous glycopeptide resistance among invasive MRSA is uncommon.
Co-resistances among clindamycin-resistant MRSA lead to therapeutic issues.
Emergence of Staphylococcus lugdunensis from joint and bone infections should be monitored.
Linezolid resistance arises from invasive coagulase-negative staphylococci.
Clonal spread of a cfr-harbouring ST2 Staphylococcus epidermidis clone is of concern.